Inflammation and Atherosclerosis
TL;DR: New insights into inflammation in atherosclerosis not only increase the understanding of this disease, but also have practical clinical applications in risk stratification and targeting of therapy for this scourge of growing worldwide importance.
read more
Abstract: Atherosclerosis, formerly considered a bland lipid storage disease, actually involves an ongoing inflammatory response. Recent advances in basic science have established a fundamental role for inflammation in mediating all stages of this disease from initiation through progression and, ultimately, the thrombotic complications of atherosclerosis. These new findings provide important links between risk factors and the mechanisms of atherogenesis. Clinical studies have shown that this emerging biology of inflammation in atherosclerosis applies directly to human patients. Elevation in markers of inflammation predicts outcomes of patients with acute coronary syndromes, independently of myocardial damage. In addition, low-grade chronic inflammation, as indicated by levels of the inflammatory marker C-reactive protein, prospectively defines risk of atherosclerotic complications, thus adding to prognostic information provided by traditional risk factors. Moreover, certain treatments that reduce coronary risk also limit inflammation. In the case of lipid lowering with statins, this anti-inflammatory effect does not appear to correlate with reduction in low-density lipoprotein levels. These new insights into inflammation in atherosclerosis not only increase our understanding of this disease, but also have practical clinical applications in risk stratification and targeting of therapy for this scourge of growing worldwide importance.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.
Terry A. Jacobson,Kevin C. Maki,Carl E. Orringer,Peter B. Jones,Penny M. Kris-Etherton,Geeta Sikand,Ralph La Forge,Stephen R. Daniels,Don P. Wilson,Pamela B. Morris,Robert A. Wild,Scott M. Grundy,Martha L. Daviglus,Keith C. Ferdinand,Krishnaswami Vijayaraghavan,Prakash Deedwania,Judith A. Aberg,Katherine P. Liao,James M. McKenney,Joyce L. Ross,Lynne T. Braun,Matthew K. Ito,Harold E. Bays,W. Virgil Brown +23 more
TL;DR: This document represents a continuation of the National Lipid Association recommendations developed by a diverse panel of experts who examined the evidence base and provided recommendations regarding the following topics: lifestyle therapies and strategies to improve patient outcomes by increasing adherence and using team-based collaborative care.
802
A systematic review and meta-analyses on C-reactive protein in relation to periodontitis.
TL;DR: There is strong evidence from cross-sectional studies that plasma CRP in periodontitis is elevated compared with controls and there is modest evidence on the effect of periodontal therapy in lowering the levels of CRP.
800
Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy
TL;DR: This review focuses on non-αT forms of vitamin E with respect to their metabolism, anti-inflammatory effects and mechanisms, and in vivo efficacy in preclinical models as well as human clinical intervention studies.
799
Metabolic syndrome update
TL;DR: The metabolic syndrome is a multiplex risk factor for atherosclerotic cardiovascular disease and type 2 diabetes and at times, drug therapies or bariatric surgery may be required to control more overt risk factors.
796
Reactive oxygen species in cardiovascular disease.
Koichi Sugamura,John F. Keaney +1 more
TL;DR: The understanding of reactive oxygen species has evolved to the point at which it is now realize these species have important roles in physiology as well as pathophysiology, and it is overly simplistic to assume a general antioxidant strategy will yield specific effects on cardiovascular disease.
787
References
Atherosclerosis — An Inflammatory Disease
TL;DR: Atherosclerosis is an inflammatory disease as discussed by the authors, and it is a major cause of death in the United States, Europe, and much of Asia, despite changes in lifestyle and use of new pharmacologic approaches to lower plasma cholesterol concentrations.
21.2K
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
TL;DR: The addition of the measurement of C-reactive protein to screening based on lipid levels may provide an improved method of identifying persons at risk for cardiovascular events.
6.2K
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
TL;DR: The reduction associated with the use of aspirin in the risk of a first myocardial infarction appears to be directly related to the level of C-reactive protein, raising the possibility that antiinflammatory agents may have clinical benefits in preventing cardiovascular disease.
5.7K
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs,Michael Clearfield,Stephen E. Weis,Edwin J. Whitney,Deborah R. Shapiro,Polly A. Beere,Alexandra Langendorfer,Evan A. Stein,William Kruyer,Antonio M. Gotto +9 more
TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
5.5K